Wayne Holman is the Founder Ridgeback Capital & Co-Founder Ridgeback Biotherapeutics
Miami, FL
Joined August 2016
- Tweets22
- Following269
- Followers311
- Likes1
Ridgeback received FDA priority review for ansuvimab to treat Ebola and will donate free drug for those in need in Africa during this ongoing Ebola outbreak. businesswire.com/news/home/2…
Happy to join forces to vanquish SARS-CoV-2 with our great partner Merck $MRK
businesswire.com/news/home/2…
Thanks to the great team at Ridgeback Bio for getting this promising medicine to patients in record time. businesswire.com/news/home/2…
MHRA clearance Thursday April 9. 80 people screened for Phase 1 on Good Friday. 1st person to receive EIDD-2801 this morning in the UK. Amazing teamwork. Fastest trial start ever. Go Ridgeback Go. #CureCovid19 #Covid19 #Ridgebackbio
prnewswire.com/news-releases…
Thanks to Tim Sheahan, Mark Denison, Ralph Baric, George Painter, Wendy Painter for all the great research on EIDD-2801. Human trials to start in days. #COVID19 #CURECOVID
Here is our new paper on an oral #antiviral drug that works against #SARSCoV2 #COVID19. A herculean effort w/ Amy Sims @Ardinajp @mariagoneviral @DenisonLab @KDinnon @aschaefe29 @SarahRLeist @Baric_Lab @DenisonLab @knowerofrandom stm.sciencemag.org/content/e…
Ridgeback to start human testing on EIDD-2801 within days. Oral investigational drug. Animal data in MERS and SARS shows early treatment prevents severe illness. We hope to prove the same in people with COVID-19. #COVID19 #CURECOVID19
Ridgeback announced today FDA cleared EIDD-2801 IND last Friday. Thank you FDA Comm. Hahn and Anti-Viral Division. So fast. So helpful. #COVID19 #FDA #EIDD2801 #RidgebackBiotherapeutics
Questions
1)Is there a relationship between severity of COVID-19 in 30-50 year olds and the exposure to RCCVs from kids through household (parents) and professional (MDs and teachers) contact?
2)Would greater prior exposure the RCCVs result in a milder COVID-19 disease course?
8)Prevalence of anti-RCCV antibodies declines with age in older adults
9)Antibodies to the RCCVs, SARS-COV-1 and MERS isolated from human samples can have some cross reactivity to each other
6)Adults with children are more frequently infected with the 4 RCCVs relative to adults without children
7)Teachers and pediatricians are more likely to be infected with the 4 RCCVs
3)Children are less likely to have severe disease with SARS-COV2
4)Younger kids will have had less exposure to RCCVs vs older kids
5)Within childhood age groups the youngest are more likely to have severe disease
Data reported in the medical literature:
1)There are 4 routinely circulating coronaviruses (RCCVs) that cause mild disease
2)Children are more routinely infected vs adults with the 4 RCCVs in published studies of subjects in NYC and China
Flattening the Curve: The South Korean Approach to COVID-19 medium.com/@stevejang/flatte…
What do we need to stop COVID? An oral, safe, effective drug! EIDD-2801 is all that in animals. On to human testing soon. #CLEARTHEPATH #Coronavirus #COVID